Bradley Duffy

Array ( [id] => 13675223 [patent_doc_number] => 20160376345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => FIBRONECTIN-BASED BINDING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 14/729718 [patent_app_country] => US [patent_app_date] => 2015-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14729718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10430281 [patent_doc_number] => 20150315294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'ACCEPTOR FRAMEWORK FOR CDR GRAFTING' [patent_app_type] => utility [patent_app_number] => 14/706484 [patent_app_country] => US [patent_app_date] => 2015-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10359 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14706484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10340479 [patent_doc_number] => 20150225484 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-13 [patent_title] => 'ANTIGEN-BINDING MOLECULE AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/696754 [patent_app_country] => US [patent_app_date] => 2015-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 13570 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14696754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11421361 [patent_doc_number] => 20170029505 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'MULTIMERIC FC PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/303625 [patent_app_country] => US [patent_app_date] => 2015-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 12904 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 22 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15303625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11698868 [patent_doc_number] => 09688771 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-27 [patent_title] => 'Anti P2X7 receptor antibodies and fragments thereof' [patent_app_type] => utility [patent_app_number] => 14/671254 [patent_app_country] => US [patent_app_date] => 2015-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 23058 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14671254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10491252 [patent_doc_number] => 20150376273 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-31 [patent_title] => 'ANTIBODIES TO NTB-A' [patent_app_type] => utility [patent_app_number] => 14/670126 [patent_app_country] => US [patent_app_date] => 2015-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 46052 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14670126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11177994 [patent_doc_number] => 09409979 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-09 [patent_title] => 'Acceptor framework for CDR grafting' [patent_app_type] => utility [patent_app_number] => 14/644441 [patent_app_country] => US [patent_app_date] => 2015-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10333 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14644441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10374427 [patent_doc_number] => 20150259433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-17 [patent_title] => 'ANTI-MESOTHELIN ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/645411 [patent_app_country] => US [patent_app_date] => 2015-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 15507 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14645411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11364067 [patent_doc_number] => 20170002046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS' [patent_app_type] => utility [patent_app_number] => 15/125142 [patent_app_country] => US [patent_app_date] => 2015-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 51815 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15125142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13675189 [patent_doc_number] => 20160376328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-29 [patent_title] => PROTEINS COMPRISING AMINO-TERMINAL PROXIMAL SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS AND CELL-TARGETING IMMUNOGLOBULIN-TYPE BINDING REGIONS [patent_app_type] => utility [patent_app_number] => 15/125126 [patent_app_country] => US [patent_app_date] => 2015-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45302 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15125126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12106305 [patent_doc_number] => 09862775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof' [patent_app_type] => utility [patent_app_number] => 14/639679 [patent_app_country] => US [patent_app_date] => 2015-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 13182 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14639679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12106305 [patent_doc_number] => 09862775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-09 [patent_title] => 'Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof' [patent_app_type] => utility [patent_app_number] => 14/639679 [patent_app_country] => US [patent_app_date] => 2015-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 13182 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14639679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10354953 [patent_doc_number] => 20150239958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-27 [patent_title] => 'PROCESS FOR THE MODULATION OF THE ANTAGONISTIC ACTIVITY OF A MONOCLONAL ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/631301 [patent_app_country] => US [patent_app_date] => 2015-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 14803 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14631301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10529021 [patent_doc_number] => 09255149 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-09 [patent_title] => 'Cytotoxic immunoglobulin' [patent_app_type] => utility [patent_app_number] => 14/629760 [patent_app_country] => US [patent_app_date] => 2015-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 49 [patent_no_of_words] => 32366 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14629760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10483322 [patent_doc_number] => 20150368341 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-24 [patent_title] => 'POLYPEPTIDES AND ANTIBODIES DERIVED FROM CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/630262 [patent_app_country] => US [patent_app_date] => 2015-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 24211 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14630262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10980006 [patent_doc_number] => 20160176950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-23 [patent_title] => 'Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods' [patent_app_type] => utility [patent_app_number] => 14/624483 [patent_app_country] => US [patent_app_date] => 2015-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 15732 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14624483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10292255 [patent_doc_number] => 20150177253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-25 [patent_title] => 'TUMOR SUPPRESSOR DESIGNATED TS10Q23.3' [patent_app_type] => utility [patent_app_number] => 14/618861 [patent_app_country] => US [patent_app_date] => 2015-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 56476 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14618861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11107643 [patent_doc_number] => 20160304613 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'NEUROPILIN ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 14/616415 [patent_app_country] => US [patent_app_date] => 2015-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 32830 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14616415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11901995 [patent_doc_number] => 09771419 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-26 [patent_title] => 'Antagonistic human light-specific human monoclonal antibodies' [patent_app_type] => utility [patent_app_number] => 14/611965 [patent_app_country] => US [patent_app_date] => 2015-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 58 [patent_no_of_words] => 69199 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 218 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14611965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11290497 [patent_doc_number] => 20160340429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-24 [patent_title] => 'IMMUNOMODULATORY AGENTS' [patent_app_type] => utility [patent_app_number] => 15/111102 [patent_app_country] => US [patent_app_date] => 2015-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 12448 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15111102 [rel_patent_id] =>[rel_patent_doc_number] =>)